P
ProQR Therapeutics
Develops RNA therapies to potentially transform the lives of patients suffering from genetic rare diseases
About ProQR Therapeutics
ProQR Therapeutics is a clinical-stage biotechnology company focused on discovering and developing RNA therapies for severe genetic disorders, particularly those affecting the retina. The company operates in the biopharmaceutical sector, targeting rare genetic eye diseases such as Leber congenital amaurosis (LCA) and Usher syndrome. ProQR's business model revolves around advancing its proprietary RNA editing technologies, like Axiomer, through clinical trials and securing regulatory approvals. The company generates revenue through licensing agreements, collaborations, and potential future sales of approved therapies. ProQR primarily serves patients with inherited retinal diseases, healthcare providers, and research institutions. The market it operates in is highly specialized, focusing on genetic ophthalmology. The company's financial health is supported by investments, grants, and strategic partnerships.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Leiden, Netherlands
- Listing
- IPO 2014
- Employees
- 203
- Open positions
- 5
- Dealroom signal
- 77.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Ophthalmology, Drug Development, DNA, Genetics and genomics, Eye Diseases, Patient Care, RNA, Disease
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2026 | $50M | — | Eli Lilly | ↗ |
| POST IPO EQUITYOther financing | Dec 2024 | $8.1M | — | Rett Syndrome Research Trust | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $15M | -12.5% | −$42M | -274.3% |
| 2025 | $17M | -15.9% | −$42M | -240% |
| 2024 | $21M | +98.5% | −$27M | -127.6% |
| 2023 | $10M | +98.4% | −$32M | -301.6% |
| 2022 | $5.3M | +100.3% | −$65M | -1236.7% |
| 2021 | $2.6M | -74.6% | −$61M | -2310.2% |
| 2020 | $10M | — | −$54M | -523.3% |
Growth signals
Latest recorded traffic for ProQR Therapeutics is 9.9K monthly website visits, down 10% over the last three months. ProQR Therapeutics's team grew 1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Rett Syndrome Research Trust
Series B and later3 investors entered at this stage
Pontifax Funds
Kreos Capital
Eli Lilly
Other known investors6 additional known investors
Foresite Capital
Gilde Healthcare- MVMedison Ventures
Netherlands Enterprise Agency (RVO)
Retinal Degeneration Fund
Sofinnova Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ProQR Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ProQR Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.